GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ME Therapeutics Holding Inc (XCNQ:METX) » Definitions » Change In Payables And Accrued Expense

ME Therapeutics Holding (XCNQ:METX) Change In Payables And Accrued Expense : C$-0.08 Mil (TTM As of Feb. 2024)


View and export this data going back to 2023. Start your Free Trial

What is ME Therapeutics Holding Change In Payables And Accrued Expense?

ME Therapeutics Holding's Change In Payables And Accrued Expense for the quarter that ended in Feb. 2024 was C$-0.04 Mil. It means ME Therapeutics Holding's Accounts Payable & Accrued Expense declined by C$0.04 Mil from Nov. 2023 to Feb. 2024 .

ME Therapeutics Holding's Change In Payables And Accrued Expense for the fiscal year that ended in Aug. 2023 was C$0.04 Mil. It means ME Therapeutics Holding's Accounts Payable & Accrued Expense increased by C$0.04 Mil from Aug. 2022 to Aug. 2023 .

ME Therapeutics Holding Change In Payables And Accrued Expense Historical Data

The historical data trend for ME Therapeutics Holding's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ME Therapeutics Holding Change In Payables And Accrued Expense Chart

ME Therapeutics Holding Annual Data
Trend Aug22 Aug23
Change In Payables And Accrued Expense
0.01 0.04

ME Therapeutics Holding Quarterly Data
Aug22 Dec22 May23 Aug23 Nov23 Feb24
Change In Payables And Accrued Expense Get a 7-Day Free Trial 0.04 - 0.03 -0.07 -0.04

ME Therapeutics Holding Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ME Therapeutics Holding Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of ME Therapeutics Holding's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

ME Therapeutics Holding (XCNQ:METX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ME Therapeutics Holding Inc (XCNQ:METX) » Definitions » Change In Payables And Accrued Expense
Comparable Companies
Traded in Other Exchanges
Q9T:Germany
Address
177 Robson Street, Vancouver, BC, CAN, V6B 0N3
Website
https://www.metherapeutics.com
ME Therapeutics Holding Inc operates its business through ME Therapeutics. It is a preclinical-stage biotechnology company working on novel cancer-fighting drugs in the field of Immuno-Oncology (IO). It is developing preclinical data for its myeloid-targeted candidate assets using validated cancer models.

ME Therapeutics Holding (XCNQ:METX) Headlines

No Headlines